StreetInsider.com News Articles

Form 6-K NYMOX PHARMACEUTICAL For: Jun 02

Wed, 03 Jun 2026 09:59:00 -0400

si-local-file:///var/storage/secattach/20260603/26596822.html

Form 6-K NYMOX PHARMACEUTICAL For: Jun 02

Wed, 03 Jun 2026 09:59:00 -0400

si-local-file:///var/storage/secattach/20260603/26596822.html

Form 6-K NYMOX PHARMACEUTICAL For: Jun 02

Wed, 03 Jun 2026 09:59:00 -0400

si-local-file:///var/storage/secattach/20260603/26596822.html

NYMOX Provides Current Update

Tue, 02 Jun 2026 16:00:00 -0400

IRVINE, CA / ACCESS Newswire / June 2, 2026 / Nymox Pharmaceutical Corporation ("Nymox", "The Company") (OTCQB:NYMXF) reports that its plans for Nymozarfex (TM) are currently focused on re-submission in the US for marketing approval. The initial US submission was not accepted to be reviewed.

The Company's subsequent 2 submissions to Denmark and UK agencies were both accepted for full review but were initially refused and will require updated re-submission and re-review if the Company decides to pursue EU approvals further. The UK refused the application after review, and while the Company will

NYMOX Provides Current Update

Tue, 02 Jun 2026 16:00:00 -0400

Form 6-K NYMOX PHARMACEUTICAL For: Mar 27

Fri, 27 Mar 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260327/26234065.html

Form 6-K NYMOX PHARMACEUTICAL For: Mar 27

Fri, 27 Mar 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260327/26234065.html

Form 6-K NYMOX PHARMACEUTICAL For: Mar 27

Fri, 27 Mar 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260327/26234065.html

NYMOX Provides Recent Updates

Fri, 27 Mar 2026 16:00:00 -0400

IRVINE, CA / ACCESS Newswire / March 27, 2026 / Nymox Pharmaceutical Corporation ("Nymox", "The Company") (OTCQB:NYMXF) will be shortly updating the Board of Directors. Patrick Doody has retired from the Board. The Company gratefully acknowledges with thanks to Mr. Doody for his service starting in 2023.

The Company is pleased to announce that while no major approvals have yet been achieved, the dossiers for its prostate treatments have been significantly updated and improved, and the Company believes it is in strong shape.

Nymox CEO Dr. Averback recently purchased 50,000 shares of NYMX in

NYMOX Provides Recent Updates

Fri, 27 Mar 2026 16:00:00 -0400

Nymox CEO Dr. Averback recently purchased 50,000 shares of NYMX in

Nymox Announces Dismissal of Delaware Action Against Ascella

Tue, 11 Mar 2025 13:51:00 -0400

IRVINE, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Nymox announces that it dismissed the Delaware matter pending against Ascella on March 7, 2025. A number of factors caused the company to reconsider its strategy to adequately protect its shareholders.

Nymox CEO Paul Averback said, "The dismissal at this stage is a legal step after consultation with counsel, with whom we have full confidence. We assure our shareholders that further steps are contemplated and we will report accordingly at the appropriate time."

About NYMOX

Nymox has submitted applications seeking the approval to, and

Nymox Announces Dismissal of Delaware Action Against Ascella

Tue, 11 Mar 2025 13:51:00 -0400

About NYMOX

Nymox has submitted applications seeking the approval to, and

Nymox Announces Dismissal of Delaware Action Against Ascella

Tue, 11 Mar 2025 13:51:00 -0400

About NYMOX

Nymox has submitted applications seeking the approval to, and

Nymox Announces Dismissal of Delaware Action Against Ascella

Tue, 11 Mar 2025 13:51:00 -0400

About NYMOX

Nymox has submitted applications seeking the approval to, and

Nymox Announces Dismissal of Delaware Action Against Ascella

Tue, 11 Mar 2025 13:51:00 -0400

About NYMOX

Nymox has submitted applications seeking the approval to, and

Nymox Announces Dismissal of Delaware Action Against Ascella

Tue, 11 Mar 2025 13:51:00 -0400

About NYMOX

Nymox has submitted applications seeking the approval to, and

Nymox Annual Report

Thu, 18 Jul 2024 13:24:00 -0400

IRVINE, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that its Annual Report is and has been in progress since late February, soon after Nymox received some of its corporate documents withheld by the terminated officers and directors. Unfortunately, this has caused delays beyond the Company’s control in its completion. The Company believes that the audit will be completed soon, and it will issue its annual report as soon as possible thereafter.

About NYMOX